PainReform Ltd. (PRFX)
- Previous Close
0.8290 - Open
0.8110 - Bid --
- Ask --
- Day's Range
0.8000 - 0.8540 - 52 Week Range
0.4170 - 26.4100 - Volume
69,943 - Avg. Volume
148,172 - Market Cap (intraday)
2.113M - Beta (5Y Monthly) 0.73
- PE Ratio (TTM)
-- - EPS (TTM)
-7.1400 - Earnings Date May 15, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
www.painreform.com7
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: PRFX
Performance Overview: PRFX
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PRFX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PRFX
Valuation Measures
Market Cap
2.03M
Enterprise Value
-5.91M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.28
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-53.82%
Return on Equity (ttm)
-102.34%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-9.34M
Diluted EPS (ttm)
-7.1400
Balance Sheet and Cash Flow
Total Cash (mrq)
8.03M
Total Debt/Equity (mrq)
1.19%
Levered Free Cash Flow (ttm)
-3.56M
Research Analysis: PRFX
Company Insights: PRFX
PRFX does not have Company Insights